File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Impact of fractionated stereotactic body radiotherapy on liver function in patients with hepatitis B virus-related hepatocellular carcinoma: Clinical and dosimetric analysis

TitleImpact of fractionated stereotactic body radiotherapy on liver function in patients with hepatitis B virus-related hepatocellular carcinoma: Clinical and dosimetric analysis
Authors
KeywordsHepatitis B virus
Radiosurgery
Hepatocellular
Carcinoma
Issue Date2013
Citation
Hong Kong Journal of Radiology, 2013, v. 16, n. 2, p. 94-99 How to Cite?
AbstractObjectives: To investigate the impact of fractionated stereotactic body radiotherapy (SBRT) on liver function and identify any dosimetric parameters that may predict deterioration of liver Junction in patients with hepatitis B (HBV)-related hepatocellular carcinoma (HCC). Methods: Thirty-six eligible patients with HBV-related HCC who were treated with fractionated SBRT between January 2008 and December 2010 were assessed. The treatment prescription ranged Jrom 20 to 40 Gy (median, 32 Gy) in 5 to 10 fractions over 1 to 2 weeks. All the patients received pre-emptive antiviral therapy. The median gross tumour volume was 509 cm3 (range, 2-3088 cm3). Four liver toxicity endpoints were assessed: (1) rate of HBV reactivation; (2) rate of chronic hepatitis B exacerbation; (3) rate of radiotherapy-induced liver disease; and (4) rate of deterioration in Child-Pugh class. Clinical and dosimetric parameters were evaluated to identify the significant predictors of liver toxicity. Results: No patient developed HBV reactivation, chronic hepatitis B exacerbation, or radiotherapy-induced liver disease within 3 months after SBRT. Four (11%) experienced Child-Pugh class deterioration. On univariate analysis, no clinical and dosimetric parameters were identified as predictors ojChild-Pugh class deterioration. Conclusion: SBRT with individualised dosing oj up to 40 Gy in 10 fractions can be delivered safely to patients with large unresectable HBV-related HCC in palliative setting. Pre-emptive antiviral therapy is probably mandatory to prevent HBV-related complications in this setting. © 2013 Hong Kong College of Radiologists.
Persistent Identifierhttp://hdl.handle.net/10722/223110
ISSN
2015 SCImago Journal Rankings: 0.113

 

DC FieldValueLanguage
dc.contributor.authorChoi, C. K K-
dc.contributor.authorLee, F. A S-
dc.contributor.authorLam, T. C.-
dc.contributor.authorWong, F. C S-
dc.contributor.authorWong, V. Y.-
dc.contributor.authorLui, C.-
dc.contributor.authorSze, W. K.-
dc.contributor.authorTung, S. Y.-
dc.date.accessioned2016-02-19T02:37:46Z-
dc.date.available2016-02-19T02:37:46Z-
dc.date.issued2013-
dc.identifier.citationHong Kong Journal of Radiology, 2013, v. 16, n. 2, p. 94-99-
dc.identifier.issn2223-6619-
dc.identifier.urihttp://hdl.handle.net/10722/223110-
dc.description.abstractObjectives: To investigate the impact of fractionated stereotactic body radiotherapy (SBRT) on liver function and identify any dosimetric parameters that may predict deterioration of liver Junction in patients with hepatitis B (HBV)-related hepatocellular carcinoma (HCC). Methods: Thirty-six eligible patients with HBV-related HCC who were treated with fractionated SBRT between January 2008 and December 2010 were assessed. The treatment prescription ranged Jrom 20 to 40 Gy (median, 32 Gy) in 5 to 10 fractions over 1 to 2 weeks. All the patients received pre-emptive antiviral therapy. The median gross tumour volume was 509 cm3 (range, 2-3088 cm3). Four liver toxicity endpoints were assessed: (1) rate of HBV reactivation; (2) rate of chronic hepatitis B exacerbation; (3) rate of radiotherapy-induced liver disease; and (4) rate of deterioration in Child-Pugh class. Clinical and dosimetric parameters were evaluated to identify the significant predictors of liver toxicity. Results: No patient developed HBV reactivation, chronic hepatitis B exacerbation, or radiotherapy-induced liver disease within 3 months after SBRT. Four (11%) experienced Child-Pugh class deterioration. On univariate analysis, no clinical and dosimetric parameters were identified as predictors ojChild-Pugh class deterioration. Conclusion: SBRT with individualised dosing oj up to 40 Gy in 10 fractions can be delivered safely to patients with large unresectable HBV-related HCC in palliative setting. Pre-emptive antiviral therapy is probably mandatory to prevent HBV-related complications in this setting. © 2013 Hong Kong College of Radiologists.-
dc.languageeng-
dc.relation.ispartofHong Kong Journal of Radiology-
dc.subjectHepatitis B virus-
dc.subjectRadiosurgery-
dc.subjectHepatocellular-
dc.subjectCarcinoma-
dc.titleImpact of fractionated stereotactic body radiotherapy on liver function in patients with hepatitis B virus-related hepatocellular carcinoma: Clinical and dosimetric analysis-
dc.typeArticle-
dc.description.natureLink_to_subscribed_fulltext-
dc.identifier.doi10.12809/hkjrl312147-
dc.identifier.scopuseid_2-s2.0-84880863540-
dc.identifier.volume16-
dc.identifier.issue2-
dc.identifier.spage94-
dc.identifier.epage99-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats